Zosano Pharma Corp
NASDAQ:ZSAN
Intrinsic Value
Zosano Pharma Corp is a US-based company operating in Health Care Equipment & Supplies industry. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ZSAN.
Zosano Pharma Corp's market capitalization is 9.8m USD.
ZSAN stock price is 1 USD.
ZSAN.
ZSAN. Open DCF Valuation
ZSAN. Open Relative Valuation
ZSAN.
ZSAN's Revenue has grown by an exceptional 38% over the past 12 months.
ZSAN's short-term assets (16m USD) exceed its short-term liabilties (10m USD).
ZSAN's ROE (Return on Equity) has significantly decreased in the last 3 years from -98% to -193%, and is approaching profitability.
ZSAN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -92% to -136%, and is approaching profitability.
ZSAN's long-term assets (26m USD) exceed its long-term liabilties (12m USD).
ZSAN has negative Operating Income for the last twelve months.
ZSAN has negative Net Income for the last twelve months.
ZSAN's ROE (Return on Equity) for the past 12 months is negative and is equal to -193%.
ZSAN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -136%.
ZSAN has negative Free Cash Flow for the last twelve months.
ZSAN has negative three-year average ROE (Return on Equity): -201%. The company is not efficient at transforming stockholders' equity into net income.
ZSAN has negative three-year average ROIC (Return on Invested Capital): -152%. The company is not efficient at using invested capital to generate operating income.
ZSAN's D/E (Debt to Equity) is very low and is equal to 0.
ZSAN's Altman Z-Score is very low and is equal to -21.38.
ZSAN doesn't generate enough operating income (-31m USD) to safely cover interest payments on its debt (500k USD).
Fundamental Analysis
Zosano Pharma Corp
Balance Sheet Decomposition
Zosano Pharma Corp
| Current Assets | 15.6m |
| Cash & Short-Term Investments | 13.5m |
| Receivables | 110k |
| Other Current Assets | 2m |
| Non-Current Assets | 10.8m |
| PP&E | 10.4m |
| Other Non-Current Assets | 460k |
| Current Liabilities | 9.7m |
| Accounts Payable | 3.7m |
| Accrued Liabilities | 3.6m |
| Other Current Liabilities | 2.4m |
| Non-Current Liabilities | 2.7m |
| Other Non-Current Liabilities | 2.7m |
Earnings Waterfall
Zosano Pharma Corp
|
Revenue
|
660k
USD
|
|
Operating Expenses
|
-31.5m
USD
|
|
Operating Income
|
-30.9m
USD
|
|
Other Expenses
|
-24.3m
USD
|
|
Net Income
|
-55.2m
USD
|
Free Cash Flow Analysis
Zosano Pharma Corp
What is Free Cash Flow?
ZSAN Profitability Score
Profitability Due Diligence
Zosano Pharma Corp's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Zosano Pharma Corp's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
ZSAN Solvency Score
Solvency Due Diligence
Zosano Pharma Corp's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Zosano Pharma Corp's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZSAN Price Targets Summary
Zosano Pharma Corp
Ownership
ZSAN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ZSAN Price
Zosano Pharma Corp
| Average Annual Return | -61.66% |
| Standard Deviation of Annual Returns | 0.05% |
| Max Drawdown | -99% |
| Market Capitalization | 9.8m USD |
| Shares Outstanding | 9 762 500 |
| Percentage of Shares Shorted | 8.17% |
Company Profile
Zosano Pharma Corp
Country
Industry
Market Cap
Dividend Yield
Description
Zosano Pharma Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Fremont, California and currently employs 40 full-time employees. The company went IPO on 2015-01-27. Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The firm is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its transdermal microneedle system (the System). Its System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic (PK) profile compared to original dosage forms. The System consists of a three cm square to six cm square array of titanium microneedles approximately 200-350 microns in length, coated with a hydrophilic formulation of drug, mounted on an adhesive patch. The company is focused on development of its lead product candidate, M207, a formulation of zolmitriptan, which is used as an acute treatment for migraine. Its zolmitriptan formulation is delivered utilizing its system. M207 is designed to provide rapid absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract.
You don't have any saved screeners yet
